FDA grants fast track status to Oncolytics' pelareorep for anal cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- S&P 500, Nasdaq fall as investors juggle earnings, Mideast risks and tariffs
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Oil retreats from above $100, still set for weekly rise on Middle East escalation
- Why Meta, Microsoft, and Nvidia are championing open-weight AI
- Meta’s new seller app hits eBay where it hurts most
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
July 20, 2026 9:00 AM EDTDesignation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy
Third Fast Track designation in gastrointestinal cancers strengthens Oncolytics regulatory momentum and continues to advance the Companys path toward registration
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (Oncolytics or the Company), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pelareorep in combination with a... More
